Samsung Biologics signs manufacturing deals worth $668M with European company
Nov. 21, 2024
Samsung Biologics has signed agreements with a Europe-based pharmaceutical company for manufacturing services valued at over $668 million.
The contracts, set to run through December 2031, contribute to Samsung Biologics' cumulative contract value for 2024, which now exceeds $4 billion.
The company is also expanding its capabilities by adding antibody-drug conjugate (ADC) services, supported by a new dedicated facility expected to be completed by year-end.
Further expansions include the operational launch of Bio Campus II’s Plant 5 in April 2025, adding significant biomanufacturing capacity.